Observation of Breast Cancer Neoadjuvant Chemotherapy Efficacy and the Changes of Estrogen Receptor and Progesterone Receptor Expression

Objective: To investigate the changes of the expression of estrogen receptor( ER) and progesterone receptor( PR) in breast cancer before and after neoadjuvant chemotherapy. Methods: A total of 123 breast cancer patients were accepted neoadjuvant chemotherapy. Adopting immunohistochemistry Powervision method to detect protein expressions of ER,PR in cancer tissues before and after operation. The clinical pathological features and curative effects of neoadjuvant chemotherapy were observed,and the relationships between hormone receptors and clinical pathological features were analyzed. Results: The total clinical effective rate( RR) was 85. 4%,of which the clinical complete remission( CR),partial clinical response( PR) and the stable disease( SD) were 28. 5%,56. 9% and14. 6%,respectively. Five patients( 4. 1%) achieved complete pathologic remission. There was no significant correlation of age,lymph node status and clinical stages with curative effects of neoadjuvant chemotherapy( P 0. 05),while the curative effect was correlated with tumor size,ER and PR status( P 0. 05). Patients with bigger tumor size,negative ER and PR expression had better curative effect.The ER positive rate before chemotherapy was lower than that after chemotherapy( P 0. 05). In contrast,the PR positive rate before and after the chemotherapy showed no significant difference( P 0.05). Differences in ER and PR positive expression rates among patients below 50 years old,patients with different tumor size,lymph node status and clinical stages were not significant( P 0. 05); there were significant differences in ER expression among patients above 50 years old( P 0. 05). Conclusion: The ER and PR status of breast cancer and neoadjuvant chemotherapy may have correlation. The neoadjuvant chemotherapy had effects on ER expression,but no effect on PR expression.